Digital Transformation in Regulatory: Achieving Excellence Virtually

Industry trends

The COVID-19 pandemic demanded significant pivots in how life sciences professionals and regulators carried out their responsibilities. Remote working was imposed in many regions to minimize the spread of disease, so technology became critical for continued regulatory operations, including carrying out virtual inspections to assess drug safety and adherence to good manufacturing practices (GMP).

This was a substantial change. A survey we conducted with Informa Pharma Intelligence showed that before the onset of the pandemic 57% of respondents had never undertaken a virtual inspection. However, such rapid digital adoption was essential and a direct reaction to continue operations, which would undoubtedly have taken longer to become widely accepted without the catalyst of the pandemic.

Read our whitepaper to see the full results of the survey and learn more about the benefits and challenges virtual inspections impose on participating organizations.